Who are Precedex's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Flivas, Dapiprazole Hydrochloride, Hytrin, Sudafed PE, Levonordefrin, Bupivacaine Hydrochloride And Epinephrine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dexmedetomidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Precedex — Competitive Intelligence Brief

Precedex (dexmedetomidine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Central alpha-2 Adrenergic Agonist. Area: Neuroscience.

marketed Central alpha-2 Adrenergic Agonist Alpha-1D adrenergic receptor Neuroscience Live · refreshed every 30 min

Target snapshot

Precedex (dexmedetomidine) — Bioxcel. Precedex works by activating alpha-2 adrenergic receptors in the brain, which reduces the activity of neurons and produces sedative effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Precedex TARGET	dexmedetomidine	Bioxcel	marketed	Central alpha-2 Adrenergic Agonist	Alpha-1D adrenergic receptor	1999-01-01
Flivas	NAFTOPIDIL	Asahi Kasei	marketed	naftopidil	Alpha-1D adrenergic receptor	1999-01-01
Dapiprazole Hydrochloride	DAPIPRAZOLE	Fera Pharms	marketed	alpha-Adrenergic Blocker	Alpha-1D adrenergic receptor	1990-01-01
Hytrin	TERAZOSIN		marketed	alpha-Adrenergic Blocker	Alpha-1D adrenergic receptor	1987-01-01
Sudafed PE	phenylephrine	Generic (multiple manufacturers)	marketed	Alpha-1 adrenergic agonist (decongestant/vasopressor)	Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor	1976-01-01
Levonordefrin	corbadrine	Eastman Kodak	marketed	corbadrine	Alpha-1D adrenergic receptor, Adrenergic receptor alpha-2, Adrenergic receptor alpha-1	1960-01-01
Bupivacaine Hydrochloride And Epinephrine	Epinephrine	Pfizer Inc.	marketed	alpha-Adrenergic Agonist [EPC]	Alpha-1D adrenergic receptor	1948-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-12-12 — Bupivacaine Hydrochloride And Epinephrine · 11590286 · Formulation · US
2027-02-27 — Bupivacaine Hydrochloride And Epinephrine · 8206360 · Formulation · US
2028-03-12 — Bupivacaine Hydrochloride And Epinephrine · 7947017 · Formulation · US
2028-11-25 — Bupivacaine Hydrochloride And Epinephrine · 8231573 · Formulation · US
2029-04-10 — Bupivacaine Hydrochloride And Epinephrine · 8226610 · Formulation · US
2029-11-02 — Bupivacaine Hydrochloride And Epinephrine · 8021344 · Formulation · US
2035-03-13 — Bupivacaine Hydrochloride And Epinephrine · 9119876 · Formulation · US
2035-03-13 — Bupivacaine Hydrochloride And Epinephrine · 9295657 · Method of Use · US
2035-03-13 — Bupivacaine Hydrochloride And Epinephrine · 10130592 · Formulation · US
2035-03-13 — Bupivacaine Hydrochloride And Epinephrine · 12280024 · Formulation · US
2036-10-20 — Bupivacaine Hydrochloride And Epinephrine · 11141540 · Formulation · US
2037-12-21 — Bupivacaine Hydrochloride And Epinephrine · 10842938 · Formulation · US
2037-12-21 — Bupivacaine Hydrochloride And Epinephrine · 10688244 · Formulation · US
2037-12-21 — Bupivacaine Hydrochloride And Epinephrine · 11771830 · Formulation · US
2038-02-06 — Bupivacaine Hydrochloride And Epinephrine · 10576156 · Formulation · US
2038-02-06 — Bupivacaine Hydrochloride And Epinephrine · 11173209 · Method of Use · US
2039-02-06 — Bupivacaine Hydrochloride And Epinephrine · 11717571 · Method of Use · US
2039-02-06 — Bupivacaine Hydrochloride And Epinephrine · 10682414 · Method of Use · US
2039-02-06 — Bupivacaine Hydrochloride And Epinephrine · 12324838 · Formulation · US
2039-02-06 — Bupivacaine Hydrochloride And Epinephrine · 11918655 · Method of Use · US
2039-02-06 — Bupivacaine Hydrochloride And Epinephrine · 11744895 · Method of Use · US
2039-02-06 — Bupivacaine Hydrochloride And Epinephrine · 11191838 · Formulation · US
2039-03-21 — Bupivacaine Hydrochloride And Epinephrine · 10653646 · Formulation · US
2039-03-21 — Bupivacaine Hydrochloride And Epinephrine · 11083698 · Method of Use · US
2039-03-21 — Bupivacaine Hydrochloride And Epinephrine · 12133837 · Formulation · US
2039-03-21 — Bupivacaine Hydrochloride And Epinephrine · 11207280 · Formulation · US
2045-01-17 — Bupivacaine Hydrochloride And Epinephrine · 12539283 · Formulation · US

Sponsor landscape (Central alpha-2 Adrenergic Agonist class)

Bioxcel · 1 drug in this class
Lavipharm · 1 drug in this class
Legacy Pharma Usa · 1 drug in this class
Promius Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Precedex — Competitive Intelligence Brief. https://druglandscape.com/ci/dexmedetomidine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab